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Abstract
Introduction:  Hemophagocytic syndrome (HFS) is a potentially lethal disorder due to an
uncontrolled immune response to a triggering agent. Our objective is to raise the importance of
HFS early diagnosis by presenting a representative case.
Case presentation: A sixteen-year-old girl with Still disease diagnosis developed a progressive
multiorgan failure including acute respiratory distress (ARDS), anemia and thrombopenia, elevated
liver enzymes, renal failure, coagulopathy with hypofibrinogenemia, and acute phase reactants
elevation despite broad-spectrum antibiotics. A bone marrow puncture-biopsy was performed, and
hemophagocytosis was found. Prolonged fever, splenomegaly, bicytopenia, hypofibrinogenemia,
hyperferritinemia and hypertriglyceridemia confirmed HFS diagnosis. She received intensive care
support therapy including mechanical ventilation and specific therapy according to HLH 2004
protocol, with a very good response.
Conclusion: Our case shows complexity of HFS diagnosis, due to septic shock-like manifestations.
Early diagnosis is essential to start appropriate treatment achieving a better outcome.
Introduction
Hemophagocytic syndrome (HFS) is a rare disorder char-
acterized by prolonged fever, cytopenias, hepatosplenom-
egaly, hypertriglyceridemia, disseminated intravascular
coagulation (DIC)-like coagulopathy and bone marrow,
spleen, liver or lymphatic nodes histiocytosis [1-3]. A sud-
den presentation, like a septic shock is possible making its
early recognition a challenging diagnosis [4]. It is well
known that HFS could be a severe complication in some
infections (mainly virals) or in some underlying diseases,
such as chronic juvenile arthritis (CJA) [3,5,6]. Moreover,
it is one of the differential diagnosis in fever of unknown
origin [7].
Taking into account that a better outcome has been
related to an early treatment [3,8], presentation of a diffi-
cult diagnosis case in a young lady could be helpful and
interesting.
Case presentation
A sixteen-year-old girl presented with rash, elevated fever
and joints swelling. She was admitted to the hospital to
make further examinations as the symptoms persisted for
15 days. A diagnosis of probable Still disease was made. In
the following days, her clinical state worsened, with per-
sistence of elevated fever. Serologic tests were negative for
Bartonella, Parvovirus B19, Rickettsia, viral hepatitis (A, B
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and C), HIV, Toxoplasma, Salmonella and Yersinia. Blood
cultures were also negative. No abnormalities were found
in abdominal and cardiac ultrasonography and in cranial
computed tomography (CT). A bone gammagraphy,
showed enhanced captation in right tibial malleolus and
in proximal interphalangeal joints of fingers 2 and 4 of
the right hand, and finger 4 of the left hand. An abdomi-
nal CT showed a biliary bladder wall enlargement and a
laparotomy was performed, but no signs of cholecystitis
were found. A broad spectrum antibiotherapy was started
with ciprofloxacin and imipenem. The patient was trans-
ferred to pediatric intensive care unit (PICU) as a conse-
quence of progressive multiorgan failure including acute
respiratory distress syndrome, liver failure, anemia,
thrombopenia and increasing acute phase reactants
(APR). On admission to PICU, the patient was on
mechanical ventilation. Examination revealed generalized
oedema, hypoventilation in both lung bases, abdominal
distension and hepatoesplenomegaly. There was also
active bleeding around puncture points and through
nasogastric tube. Blood analysis on admission is shown in
table 1.
A high positive end-expiratory pressure (PEEP) was set
due to hypoxemia (up to 14 cmH2O), with a PO2/FiO2 of
141. Thorax radiography showed bilateral diffuse infil-
trates, and slight cardiomegaly. Inotropic support was
needed (dopamine at 15 μg/kg/minute) and a perfusion
with furosemide (0.5 mg/kg/hour) was started. Labora-
tory analysis showed abnormal values for haemoglobin
(7.7 g/dL), platelets (29,000/mm3) and coagulation times
including hypofibrinogenemia (85 mg/dL). She received
red blood cell concentrates, platelets and fresh frozen
plasma. The same antibiotherapy was maintained and
acute liver failure support treatment was started.
A bone marrow puncture-biopsy was performed. Acti-
vated macrophages with hemophagocytosis were found
(figure 1), which together with the clinical and analytical
data (bicytopenia, and coagulopathy with hypofibrino-
genemia, and afterwards a ferritin of 190594 μg/L and
triglycerides of 677 mg/dL) confirmed the HFS diagnosis.
Specific treatment for this syndrome was started, follow-
ing Hemophagocytic Lymphohistiocytosis (HLH) 2004
guidelines. She had a very good response, and at forth day
from admission she was extubated to non invasive venti-
lation using a full-face mask. A progressive analytical nor-
malization was observed and she was discharged after 12
days in PICU, without any sequelae.
She is currently being followed as an outpatient. She had
two reactivations of her rheumatoid disorder, with a good
response to corticoids.
Discussion
HFS is an activation of mononuclear phagocyte system
cells, with hemophagocytosis in bone marrow and the rest
of reticuloendothelial system. This syndrome can be
either primary/familial (familial hemophagocytic lym-
phohistiocytosis – FHL) or reactive/secondary. FHL has a
recessive autosomal inheritance and it develops in chil-
Table 1: Blood analysis on admission
Hemoglobin 7,7 g/dL
Hematocrit 22,7%
Leucocytes 12.200/mm3 (with a marked left shift)
Platelets 29.000/mm3
Prothrombin rate 75%
Fibrinogen 85 mg/dL
D-dimers 6.593 ng/mL
Aspartate aminotransferase 3.257 U/L
Alanine aminotransferase 907 U/L
Direct bilirrubin directa 9,2 mg/dL
Ammonium 57 μmol/L
Creatine kinase 1.067 U/L
Dehydrogenase lactate 19.747 U/L
Lipase 48 U/L
Amylase 137 U/L
Sodium 144 mEq/L
Potassium 3,1 mEq/L
Urea 63 mg/dL
Creatinine 1,1 mg/dL
Procalcitonin 3,03 ng/mL
C reactive protein 16,7 mg/dL
Bone marrow smear (optic microscope) Figure 1
Bone marrow smear (optic microscope). Activated 
macrophages and hemophagocytosis from bone marrow 
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dren younger than 2 years, even though in rare cases it can
feature later on [9]. It is rapidly lethal and it is sometimes
related to some immunological diseases (X-linked lym-
pho-proliferative, Chediak Higashi and Griscelli syn-
dromes).
Secondary HFS has a better outcome than primary HFS. It
is triggered mainly by viral infections (especially Ebstein-
Barr virus) [10], and also by bacterial, parasitic and fungal
infections. It can also develop during malignancies and
rheumatoid disorders (kwown in this case as macrophagic
activation syndrome), as in our patient [6].
The activation of mononuclear system cells occurs due to
a hypersecretion of proinflammatory cytokines (IFNγ,
TNFα, IL6, IL10, M-CSF), as a consequence of a triggering
agent, which is often a viral infection [11]. The underlying
problem is a T and Natural Killers cells dysfunction, which
leads to an uncontrolled immunological response [12]
due to inability to eliminate the triggering agent. All viral,
bacterial, parasitic and fungal cultures performed in our
case were negative.
Impaired perforine function due to gene mutations seems
to play an important role in HFS pathogenesis, as reported
in literature [12]. They are implicated in cytotoxicity by
forming a death-inducing pore in target cell [13].
HFS diagnosis is made basing on clinical and histological
criteria. Five out of 8 criteria must be fulfilled. Absence of
hemophagocytosis does not exclude the diagnosis [2].
Multiorgan failure is the most severe presentation of HFS.
In pediatrics, multiorgan failure is usually caused by sep-
sis. In the present case, the initial diagnosis was septic
shock. Therefore, HFS has to be included between the
causes of multiorgan failure in pediatrics to permit an
early diagnosis and treatment. Central nervous system
(CNS) is often involved, which has been linked with a
poor prognosis [14]. Even though our patient developed
a very severe form of HFS, there seemed to be no CNS
involvement, and this agrees with the good outcome.
Treatment is nowadays applied according to HLH 2004
protocol, which is designed for primary HFS and also used
in severe secondary HFS cases. Aggressive immunochem-
otherapy is given (dexamethasone, cyclosporine A, etopo-
side and in patients with CNS symptoms or abnormal
CSF, also intrathecal methotrexate and corticoids) [2].
After initial treatment, bone marrow transplantation is
indicated in primary disease and in severe and persistent
secondary HFS [1].
Without treatment, this is a lethal disorder. Mortality is
high depending in reactive HFS on underlying disorder. In
Henter's study, in which 113 patients under 15 years of
age were included, survival rate at 3.1 years was 51% in
primary cases, while it was 55% in reactive ones. All
patients had received treatment according to HLH 1994
protocol [1].
Conclusion
Our patient had a very good outcome, without any seque-
lae. Early recognition of this syndrome to apply specific
therapy as well as multiorganic failure treatment in PICU,
are management key factors. HFS is probably underdiag-
nosed, as multiorgan failure is usually explained by other
more common causes like septic shock. [4]
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